New Biological Insights into CV Risk & Lipid Management: The Role of Drug Quality
R. Preston Mason, Boston, discusses new biological insights into CV risk and lipid management and the role of drug quality in this pre-recorded webinar, which has been hosted and developed by Viatris.
SPEAKER DETAILS
R. Preston Mason PhD
Brigham and Women’s Hospital, Harvard Medical School,
Boston, Massachusetts, USA
For the past 22 years, R. Preston Mason has served as a faculty memberof the Cardiovascular Division at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts, USA. R. Mason is also the President of Elucida Research, a biotechnology research institute. He has received many awards for his research in cardiovascular pharmacology over the past 30 years.
He received a full scholarship for graduate and medical advanced degrees at the University of Connecticut School of Medicine. Prior to coming to Boston, he was a professor in the medical faculties of the University of Connecticut and Drexel University.
EDUCATIONAL OBJECTIVES
Speaker: R. Preston Mason, PhD
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Title of the session: New Biological Insights into CV Risk & Lipid Management: The Role of Drug Quality
Objectives:
- Recent guidelines on cardiovascular disease prevention & dyslipidemia (snapshot)
- Why does a different statin/ have a different effect?
- What is quality medicine and why it's important?
Conclusion:
- LDL lowering reduces CV events in a proportional manner independent of baseline levels1
- Statins reduce CV risk by lowering serum LDL and by non-LDL mechanisms (reduce inflammation, improve endothelial function)2
- Atorvastatin has been shown to stop and even reverse atherosclerotic plaque progression2
- Concerns are raised over the safety of generic atorvastatin due to impurities that interfere with activity3
CV, Cardiovascular; LDL, Low-density lipoprotein
References
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.
- Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic Am J Cardiol. 2005;96(5A):11F-23F.
- Mason PR, Gerard SA, Jacob RF. Atorvastatin Generics Obtained from Multiple Sources Worldwide Contain a Methylated Impurity that Reduces Their HMG-CoA Reductase Inhibitory Pharmacological control of lipids and lipoproteins. 2013;3:287.
NON-2023-5877
RELATED CONTENT
